Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
millionaire example said 75M revenue not 750M.
750M would put you at $12 a share
EXAS company that sells Cologuard diagnostic test has multiple of 17 times revenue.
So using 17 as a multiple:
if ARYC has 75M in annual revenue X 17 = $1.275 B market cap. ($1.10 per share)
Form 15 tittle is "Termination of Registration of a Class of Security Under Section 12(b) (15-12b)". So the SEC analyst is correctly saying that that's the form ARYC filed.
But further down on the form it says:
https://www.ktvu.com/video/628515 Dr. Mark Schena discusses an all encompassing allergy test on The Four
Allergies got you down? Dr. Mark Schena joins Heather Holmes on The Four to talk about the latest way to test for allergies.
aired live on KTVU Fox 2 the Bay Area's TV News Station on 11/21/19 at 4:40pm pst.
Delsurfer, thanks for that observation. Suzanne is obviously happy the company is finally making money with the allergy test. I believe she and the family have invested tens of millions in her children's company.
Click here (even if you're not on Facebook you'll be able to watch it):
https://www.facebook.com/Arrayit/videos/427025347978151/
"Arrayit aired on KTVU news in the San Francisco Bay Area today in regards to our revolutionary new allergy blood test. We will have better video soon, but for now here it is! Thanks for watching"
https://www.facebook.com/Arrayit/videos/427025347978151/
"Arrayit aired on KTVU news in the San Francisco Bay Area today in regards to our revolutionary new allergy blood test. We will have better video soon, but for now here it is! Thanks for watching"
Actually no. There are no other companies in the US that sell a multiplex allergy blood test testing many allergens at once.
Thermo fisher has a multiplex test but is not being sold in the U.S.
If you look at the description of the Spiriplex test it fits to a t the Arrayit test.....fingerstick, 4 drops of blood on a blood card, microarray based.
https://spiriplex.com/allergies/
Spiriplex Science
There is the possibility that they have an agreement with the SEC to follow this path of not reporting for a while under form 15, and then reemerge in a few months with 2 or 3 years of latest fins. Time will tell.
You say about the form 15 "despite being filled out incorreclty".
You have no proof of that.
There is no requirement to file anything on day 90.
Actually yesterday was day 90 since they filed form 15 on 8/19.
Thanks Sloan.
You're correct.
Mark did not buy 490,000 shares for $1 in the open market.
He was awarded those shares to settle royalty payments owed to Mark when he was a consultant
If the Schenas had sold any shares they would have had to file a form 4.
There are no such forms filed since 2014
Thanks Delsurfer. That's why I thought, that the pps from 2002 to 2009 shown was for the previous shell companies. And by the way the chart says 60.000 (sixty dollars) not 60,000 like Webslinger posted.
ARYC did not become public until 2009
Case 37-2016-00026937 was dismissed. Iconic unexpectedly dropped the case.
Agreed.
Arrayit sued Iconic on 08/01/2018
Case # 37-2018-00038483 in San Diego County Superior Courts
Arrayit Corporation vs Iconic Holdings LLC
https://unicourt.com/case/urc-FVEBYIBHDBEEAI3YHA2WHDDAMNLRO0932#dockets
On 08/01/2018 a Contract - Other Contract case was filed by Arrayit Corporation against Iconic Holdings LLC in the jurisdiction of San Diego County Superior Courts, Central Courthouse located in San Diego, California.
Per ARYC they are on track for 100M billing in 2019
100M billing=approx. 40M revenue=$1. pps
Mark: "I purchased 490,000 shares of ARYC at $1 per share in 2014."
purchase definition "acquire (something) by paying for it; buy."
The pps was nowhere near $1 in 2014. Started 2014 @ 0.30 and went down from there all year, ending at 0.10.
"the Company issued 459,333 shares to Dr. Schena valued at $68,126 to fulfill its then $459,433 obligation to him for royalties"
$68,126 / 459,333 shares = 0.15 pps
For accounting purposes the company probably wrote it off at $1 per share
It's always smoke and mirrors with Mark.
If Mark had bought shares in 2014 he would have had to file a form 4 with SEC.
The last purchase he made was 7100 shares in Oct 2013
https://www.sec.gov/cgi-bin/own-disp?action=getowner&CIK=0001428650
“Doctors and nurses currently use 15 million CA-125 tests per year to monitor ovarian cancer, generating approximately $2 billion in worldwide revenue. Capturing 1% of the ovarian cancer monitoring market would generate $97.5 million in annual revenues for Arrayit and Avant through the manufacture and sale of 150,000 OvaDx® tests at $650 per test. Our Sunnyvale laboratories have more than adequate capacity to process 150,000 OvaDx® tests per year upon FDA approval.”
1% market share = $97.5M in yearly revenue
2% = $185M
and so on.
Mark and Rene did not learn from the OvaDx IP fiasco and again because of lack of funds, in 2014 they offered the IP of the Food safety test to another crook to try to raise funds for that test. We know how that turned out, tied in litigation.
I hope that now that there is money coming in, M & R are done with that business model of giving the IP's away.
I don't know anything about him.
They say in the article that the U.K. breast cancer test is 4 to 5 years away from being available.
The Arrayit ovarian cancer test could be available much sooner than that if the FDA approves it.
The sad part is that Arrayit's ovarian cancer test could have been available already if funds had been available to do the required clinical trials. Arrayit could never get funds for whatever reason, so in 2009 they gave the IP of the test to a bunch of crooks in Texas in the hopes that the crooks would raise the money. Of course they didn't, and OvaDx sat on the shelf for years hostage to the Texans.
Now that Arrayit may have the test back and has money from the allergy test revenue to do the required work, they may have submitted the test in June 2108 to the FDA for guidance.
Based on the FDA guidance given, Arrayit had to conduct more studies and formally submit the test for approval.
We don't know what else Arrayit has done with the test since the July 2018 FDA meeting, but they would have had sufficient time to do the necessary work,
Hopefully we wake up one day to good news about it.
All IMO
The ARYC science approach for oncology tests is valid. On their website they explain
"Material Information is defined as: Information, for which there is a substantial likelihood, that a reasonable investor would consider important in making his or her investment decisions, or. Information that is reasonably certain to have a substantial effect on the price of a company's securities."
"SEC would generally permit (delinquent filer) companies just to file the most recent Form 10-K and any subsequent Forms 10-Q. This approach facilitates getting to investors the most relevant, recent information....if the registrant files a comprehensive annual report on Form 10-K that includes all material information that would have been included in those (delinquent) filings."
https://www.theventurealley.com/2015/08/sec-guidance-on-catching-up-delinquent-filers/
There is no requirement, but there is a possibility that they negotiated with the SEC to file a form 15, go silent, and then reemerge 3 months later with 2 or 3 years worth of fins.
Just a posibility but something to think about
Sloan, agree with all you state. The November date is just a guesstimate based on all the public information currently available. Nobody outside Arrayit knows for sure when the filings will happen, but it could be sooner (this year) rather than later.